Immunovant Files 8-K on Financials
Ticker: IMVT · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1764013
Sentiment: neutral
Topics: financial-reporting, operations
Related Tickers: IMVT
TL;DR
IMVT filed an 8-K on Nov 10, 2025, updating financials. No major news.
AI Summary
Immunovant, Inc. filed an 8-K on November 10, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing details the company's ongoing operations and financial status without specifying any new material events or transactions.
Why It Matters
This filing provides an update on Immunovant's financial condition and operational results, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any new material information that would significantly alter the company's risk profile.
Key Players & Entities
- Immunovant, Inc. (company) — Registrant
- November 10, 2025 (date) — Filing Date
- Health Sciences Acquisitions Corp (company) — Former Company Name
- 001-38906 (other) — SEC File Number
- 832771572 (other) — IRS Employer Identification No.
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but the specific details are not provided in the excerpt.
When was this 8-K filing submitted?
The filing was submitted on November 10, 2025.
What was Immunovant, Inc.'s former name?
Immunovant, Inc.'s former name was Health Sciences Acquisitions Corp.
What is the company's principal executive office address?
The principal executive offices are located at 320 West 37th Street, New York, NY 10018.
What is the SIC code for Immunovant, Inc.?
The Standard Industrial Classification (SIC) code for Immunovant, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-11-10 07:15:38
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMVT The Nasdaq Sto
Filing Documents
- imvt-20251110.htm (8-K) — 26KB
- exhibit99120251110.htm (EX-99.1) — 129KB
- 0001764013-25-000148.txt ( ) — 279KB
- imvt-20251110.xsd (EX-101.SCH) — 2KB
- imvt-20251110_lab.xml (EX-101.LAB) — 21KB
- imvt-20251110_pre.xml (EX-101.PRE) — 12KB
- imvt-20251110_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On November 10, 2025, Immunovant, Inc., or the Company, issued a press release announcing its financial results for its fiscal second quarter and six months ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated November 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOVANT, INC. By: /s/ Tiago Girao Tiago Girao Chief Financial Officer Date: November 10, 2025